Your session is about to expire
← Back to Search
PD-1 Inhibitors + CAR T Cell Therapy for Hodgkin's Lymphoma
Study Summary
This trial will study if CAR-T cells can be used to treat cHL, and if they can be combined with PD-1 antibodies to improve clinical responses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have been diagnosed with classical Hodgkin lymphoma.I am starting standard anti-PD-1 therapy as advised by my oncologist.I had a stem cell transplant and understand the risks of anti-PD-1 therapy.I have been treated with anti-PD-1 therapy before CAR-T-cell therapy.My condition relapsed and I haven't had CD30 CAR-T therapy before.I have Hodgkin lymphoma that didn't respond to at least 3 treatments, including specific CAR-T therapies.I am willing to give blood samples for my anti-PD-1 therapy.My cancer returned after CD30 CAR-T cell therapy.You have given written permission to participate in the study and to share your personal health information.
- Group 1: Arm 1: Relapse After Prior CD30 CAR-T Therapy
- Group 2: Arm 2: Relapse with no Prior CD30 CAR-T Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what ailments is Pembrolizumab usually prescribed?
"Commonly used to address unresectable melanoma, pembrolizumab can also be administered as a treatment for microsatellite instability high and squamous cell carcinoma with an elevated risk of recurrence."
What is the upper limit of participants for this experiment?
"Affirmative. The records on clinicaltrials.gov signify that this trial is recruiting volunteers, which was initially posted on September 1st 2019 and recently updated July 22nd 2022. 20 participants are sought for the study at a single location."
Is the recruitment of participants still open for this trial?
"Affirmative. Clinicaltrials.gov verifies that this research project, which was posted in September 2019 and recently revised on July 22nd 2022 is actively recruiting patients for participation. Up to 20 individuals are needed between 1 trial site."
Have there been prior experiments utilizing Pembrolizumab?
"Currently, there are 1633 active studies involving Pembrolizumab - with 200 in the final stage of trials. The majority are taking place in Houston, Texas; however, this cancer treatment is being researched from over 73 thousand different facilities worldwide."
Share this study with friends
Copy Link
Messenger